Tekla Life Sciences Investors (HQL) Max Pain Analysis
Max pain is the strike price where aggregate option buyer payout is minimized at expiration. It represents the price at which option writers retain the most premium.
Tekla Life Sciences Investors (HQL) operates in the Financial Services sector, specifically the Asset Management industry, with a market capitalization near $533.1M, listed on NYSE, carrying a beta of 0.74 to the broader market. Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. Led by Daniel R. Omstead, public since 1992-05-01.
Max pain analysis shows the strike price where the most options expire worthless. No recent options activity for HQL as of 2026-06-02; this typically reflects low options liquidity, a recently listed name, or a temporary data feed delay. Snapshot will refresh on the next active session.